Skip to main content
Top
Published in: Current Cardiology Reports 10/2023

21-09-2023 | Myocardial Infarction | Management of Acute Coronary Syndromes (H Jneid, Section Editor)

Testosterone Replacement Therapy and Cardiovascular Disease: Balancing Safety and Risks in Hypogonadal Men

Authors: Kelli Blackwell, Michele Blackwell, Thomas Blackwell

Published in: Current Cardiology Reports | Issue 10/2023

Login to get access

Abstract

Purpose of Review

The purpose of this review is to analyze the link between testosterone replacement therapy (TRT) and adverse cardiovascular (CV) events.

Recent Findings

A few published studies suggest a link between TRT and CV events. These studies contained flaws, and many other studies reveal a reduction in CV events. Hypogonadism is associated with increased mortality in men with CVD. TRT in hypogonadal men can improve many CVD risk factors, reduce QT interval prolongation, lead to better outcomes in heart failure patients, and slow the progression of atherosclerosis.

Summary

The use of TRT to achieve physiologic testosterone concentrations in men does not pose a threat to CV health and has demonstrated a cardioprotective effect.
Literature
1.
go back to reference • Togun A, Sankar A, Karaca-Mandic P. FDA safety warnings and trends in testosterone marketing to physicians. 2022;28 The FDA modification of testosterone labels in 2015 to indicate increased risk of stroke and heart attack still exists despite many studies indicating that there is not increased risk. • Togun A, Sankar A, Karaca-Mandic P. FDA safety warnings and trends in testosterone marketing to physicians. 2022;28 The FDA modification of testosterone labels in 2015 to indicate increased risk of stroke and heart attack still exists despite many studies indicating that there is not increased risk.
3.
go back to reference Vigen R, O’Donnell CI, Barón AE, et al. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA. 2013;310:1829–36.PubMedCrossRef Vigen R, O’Donnell CI, Barón AE, et al. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA. 2013;310:1829–36.PubMedCrossRef
4.
go back to reference Finkle WD, Greenland S, Ridgeway GK, Adams JL, Frasco MA, Cook MB, Fraumeni JF, Hoover RN. Increased Risk of non-fatal myocardial infarction following testosterone therapy prescription in men. PLoS ONE. 2014;9:e85805.PubMedPubMedCentralCrossRef Finkle WD, Greenland S, Ridgeway GK, Adams JL, Frasco MA, Cook MB, Fraumeni JF, Hoover RN. Increased Risk of non-fatal myocardial infarction following testosterone therapy prescription in men. PLoS ONE. 2014;9:e85805.PubMedPubMedCentralCrossRef
5.
go back to reference Xu L, Freeman G, Cowling BJ, Schooling CM. Testosterone therapy and cardiovascular events among men: a systematic review and meta-analysis of placebo-controlled randomized trials. BMC Med. 2013;11:108.PubMedPubMedCentralCrossRef Xu L, Freeman G, Cowling BJ, Schooling CM. Testosterone therapy and cardiovascular events among men: a systematic review and meta-analysis of placebo-controlled randomized trials. BMC Med. 2013;11:108.PubMedPubMedCentralCrossRef
8.
go back to reference Gagliano-Jucá T, Basaria S. Trials of testosterone replacement reporting cardiovascular adverse events. Asian J Androl. 2018;20:131–7.PubMedCrossRef Gagliano-Jucá T, Basaria S. Trials of testosterone replacement reporting cardiovascular adverse events. Asian J Androl. 2018;20:131–7.PubMedCrossRef
9.
go back to reference Kaur H, Werstuck GH. The effect of testosterone on cardiovascular disease and cardiovascular risk factors in men: a review of clinical and preclinical data. CJC Open. 2021;3:1238–48.PubMedPubMedCentralCrossRef Kaur H, Werstuck GH. The effect of testosterone on cardiovascular disease and cardiovascular risk factors in men: a review of clinical and preclinical data. CJC Open. 2021;3:1238–48.PubMedPubMedCentralCrossRef
10.
go back to reference Gonzales JR, Goldstein I. Testosterone replacement and cardiovascular risk what do endocrinologists need to know? Cardiovascular Endocrinology & Metabolism. 2015;4:100–7.CrossRef Gonzales JR, Goldstein I. Testosterone replacement and cardiovascular risk what do endocrinologists need to know? Cardiovascular Endocrinology & Metabolism. 2015;4:100–7.CrossRef
11.
12.
go back to reference Klein CE. The hypothalamic-pituitary-gonadal axis. Holland-Frei Cancer Medicine. 6th edition. BC Decker, Hamilton (ON) 2003. Klein CE. The hypothalamic-pituitary-gonadal axis. Holland-Frei Cancer Medicine. 6th edition. BC Decker, Hamilton (ON) 2003.
13.
14.
go back to reference Aghazadeh Y, Zirkin BR, Papadopoulos V. Chapter Seven - Pharmacological regulation of the cholesterol transport machinery in steroidogenic cells of the testis. In: Litwack G, editor. Vitamins & Hormones. Academic Press; 2015. p. 189–227. Aghazadeh Y, Zirkin BR, Papadopoulos V. Chapter Seven - Pharmacological regulation of the cholesterol transport machinery in steroidogenic cells of the testis. In: Litwack G, editor. Vitamins & Hormones. Academic Press; 2015. p. 189–227.
16.
go back to reference Wilson JD. The role of 5alpha-reduction in steroid hormone physiology. Reprod Fertil Dev. 2001;13:673–8.PubMedCrossRef Wilson JD. The role of 5alpha-reduction in steroid hormone physiology. Reprod Fertil Dev. 2001;13:673–8.PubMedCrossRef
17.
go back to reference Simpson ER. Aromatase: biologic relevance of tissue-specific expression. Semin Reprod Med. 2004;22:11–23.PubMedCrossRef Simpson ER. Aromatase: biologic relevance of tissue-specific expression. Semin Reprod Med. 2004;22:11–23.PubMedCrossRef
18.
go back to reference Quigley CA, Bellis AD, Marschke KB, El-Awady MK, Wilson EM, French FS. Androgen receptor defects: historical, clinical, and molecular perspectives*. Endocr Rev. 1995;16:271–321.PubMed Quigley CA, Bellis AD, Marschke KB, El-Awady MK, Wilson EM, French FS. Androgen receptor defects: historical, clinical, and molecular perspectives*. Endocr Rev. 1995;16:271–321.PubMed
19.
go back to reference Prescott J, Coetzee GA. Molecular chaperones throughout the life cycle of the androgen receptor. Cancer Lett. 2006;231:12–9.PubMedCrossRef Prescott J, Coetzee GA. Molecular chaperones throughout the life cycle of the androgen receptor. Cancer Lett. 2006;231:12–9.PubMedCrossRef
20.
go back to reference Panizzon MS, Bree K, Hsieh T-C, Hauger R, Xian H, Jacobson K, Lyons MJ, Franz CE. Genetic variation in the androgen receptor modifies the association between testosterone and vitality in middle-aged men. J Sex Med. 2020;17:2351–61.PubMedPubMedCentralCrossRef Panizzon MS, Bree K, Hsieh T-C, Hauger R, Xian H, Jacobson K, Lyons MJ, Franz CE. Genetic variation in the androgen receptor modifies the association between testosterone and vitality in middle-aged men. J Sex Med. 2020;17:2351–61.PubMedPubMedCentralCrossRef
21.
go back to reference Chamberlain NL, Driver ED, Miesfeld RL. The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function. Nucleic Acids Res. 1994;22:3181–6.PubMedPubMedCentralCrossRef Chamberlain NL, Driver ED, Miesfeld RL. The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function. Nucleic Acids Res. 1994;22:3181–6.PubMedPubMedCentralCrossRef
22.
go back to reference Goldman AL, Bhasin S, Wu FCW, Krishna M, Matsumoto AM, Jasuja R. A reappraisal of testosterone’s binding in circulation: physiological and clinical implications. Endocr Rev. 2017;38:302–24.PubMedPubMedCentralCrossRef Goldman AL, Bhasin S, Wu FCW, Krishna M, Matsumoto AM, Jasuja R. A reappraisal of testosterone’s binding in circulation: physiological and clinical implications. Endocr Rev. 2017;38:302–24.PubMedPubMedCentralCrossRef
23.
go back to reference Ramasamy R, Golan R, Wilken N, Scovell JM, Lipshultz LI. Association of free testosterone with hypogonadal symptoms in men with near-normal total testosterone levels. Urology. 2015;86:287–90.PubMedCrossRef Ramasamy R, Golan R, Wilken N, Scovell JM, Lipshultz LI. Association of free testosterone with hypogonadal symptoms in men with near-normal total testosterone levels. Urology. 2015;86:287–90.PubMedCrossRef
24.
go back to reference Nassar GN, Leslie SW. Physiology, testosterone. StatPearls: StatPearls Publishing, Treasure Island (FL); 2023. Nassar GN, Leslie SW. Physiology, testosterone. StatPearls: StatPearls Publishing, Treasure Island (FL); 2023.
26.
27.
go back to reference Er F, Michels G, Brandt MC, Khan I, Haase H, Eicks M, Lindner M, Hoppe UC. Impact of testosterone on cardiac L-type calcium channels and Ca2+ sparks: acute actions antagonize chronic effects. Cell Calcium. 2007;41:467–77.PubMedCrossRef Er F, Michels G, Brandt MC, Khan I, Haase H, Eicks M, Lindner M, Hoppe UC. Impact of testosterone on cardiac L-type calcium channels and Ca2+ sparks: acute actions antagonize chronic effects. Cell Calcium. 2007;41:467–77.PubMedCrossRef
28.
go back to reference Albrektsen G, Heuch I, Løchen M-L, Thelle DS, Wilsgaard T, Njølstad I, Bønaa KH. Lifelong gender gap in risk of incident myocardial infarction: the Tromsø study. JAMA Intern Med. 2016;176:1673–9.PubMedCrossRef Albrektsen G, Heuch I, Løchen M-L, Thelle DS, Wilsgaard T, Njølstad I, Bønaa KH. Lifelong gender gap in risk of incident myocardial infarction: the Tromsø study. JAMA Intern Med. 2016;176:1673–9.PubMedCrossRef
29.
go back to reference Iorga A, Cunningham CM, Moazeni S, Ruffenach G, Umar S, Eghbali M. The protective role of estrogen and estrogen receptors in cardiovascular disease and the controversial use of estrogen therapy. Biol Sex Differ. 2017;8:33.PubMedPubMedCentralCrossRef Iorga A, Cunningham CM, Moazeni S, Ruffenach G, Umar S, Eghbali M. The protective role of estrogen and estrogen receptors in cardiovascular disease and the controversial use of estrogen therapy. Biol Sex Differ. 2017;8:33.PubMedPubMedCentralCrossRef
30.
go back to reference Anaissie J, DeLay KJ, Wang W, Hatzichristodoulou G, Hellstrom WJ. Testosterone deficiency in adults and corresponding treatment patterns across the globe. Transl Androl Urol. 2017;6:183–91.PubMedPubMedCentralCrossRef Anaissie J, DeLay KJ, Wang W, Hatzichristodoulou G, Hellstrom WJ. Testosterone deficiency in adults and corresponding treatment patterns across the globe. Transl Androl Urol. 2017;6:183–91.PubMedPubMedCentralCrossRef
31.
go back to reference Mulligan T, Frick M, Zuraw Q, Stemhagen A, Mcwhirter C. Prevalence of hypogonadism in males aged at least 45 years: the HIM study. Int J Clin Pract 2006;60:762–769. Mulligan T, Frick M, Zuraw Q, Stemhagen A, Mcwhirter C. Prevalence of hypogonadism in males aged at least 45 years: the HIM study. Int J Clin Pract 2006;60:762–769.
33.
go back to reference Bhasin S, Brito JP, Cunningham GR, Hayes FJ, Hodis HN, Matsumoto AM, Snyder PJ, Swerdloff RS, Wu FC, Yialamas MA. Testosterone therapy in men with hypogonadism: an endocrine society* clinical practice guideline. J Clin Endocrinol Metab. 2018;103:1715–44.PubMedCrossRef Bhasin S, Brito JP, Cunningham GR, Hayes FJ, Hodis HN, Matsumoto AM, Snyder PJ, Swerdloff RS, Wu FC, Yialamas MA. Testosterone therapy in men with hypogonadism: an endocrine society* clinical practice guideline. J Clin Endocrinol Metab. 2018;103:1715–44.PubMedCrossRef
34.
go back to reference Dandona P, Rosenberg MT. A practical guide to male hypogonadism in the primary care setting. Int J Clin Pract. 2010;64:682–96.PubMedCrossRef Dandona P, Rosenberg MT. A practical guide to male hypogonadism in the primary care setting. Int J Clin Pract. 2010;64:682–96.PubMedCrossRef
35.
go back to reference Golan R, Scovell JM, Ramasamy R. Age-Related testosterone decline is due to waning of both testicular and hypothalamic-pituitary function. Aging Male. 2015;18:201–4.PubMedPubMedCentralCrossRef Golan R, Scovell JM, Ramasamy R. Age-Related testosterone decline is due to waning of both testicular and hypothalamic-pituitary function. Aging Male. 2015;18:201–4.PubMedPubMedCentralCrossRef
36.
go back to reference Rivas AM, Mulkey Z, Lado-Abeal J, Yarbrough S. Diagnosing and managing low serum testosterone. Proc (Bayl Univ Med Cent). 2014;27:321–4.PubMed Rivas AM, Mulkey Z, Lado-Abeal J, Yarbrough S. Diagnosing and managing low serum testosterone. Proc (Bayl Univ Med Cent). 2014;27:321–4.PubMed
41.
44.
go back to reference Tsametis CP, Isidori AM. Testosterone replacement therapy: for whom, when and how? Metabolism. 2018;86:69–78.PubMedCrossRef Tsametis CP, Isidori AM. Testosterone replacement therapy: for whom, when and how? Metabolism. 2018;86:69–78.PubMedCrossRef
45.
go back to reference Rastrelli G, Guaraldi F, Reismann Y, Sforza A, Isidori AM, Maggi M, Corona G. Testosterone replacement therapy for sexual symptoms. Sexual Medicine Reviews. 2019;7:464–75.PubMedCrossRef Rastrelli G, Guaraldi F, Reismann Y, Sforza A, Isidori AM, Maggi M, Corona G. Testosterone replacement therapy for sexual symptoms. Sexual Medicine Reviews. 2019;7:464–75.PubMedCrossRef
46.
go back to reference Bassil N, Alkaade S, Morley JE. The benefits and risks of testosterone replacement therapy: a review. Ther Clin Risk Manag. 2009;5:427–48.PubMedPubMedCentral Bassil N, Alkaade S, Morley JE. The benefits and risks of testosterone replacement therapy: a review. Ther Clin Risk Manag. 2009;5:427–48.PubMedPubMedCentral
47.
go back to reference Hackett GI. Testosterone replacement therapy and mortality in older men. Drug Saf. 2016;39:117–30.PubMedCrossRef Hackett GI. Testosterone replacement therapy and mortality in older men. Drug Saf. 2016;39:117–30.PubMedCrossRef
48.
go back to reference Saad F, Aversa A, Isidori AM, Zafalon L, Zitzmann M, Gooren L. Onset of effects of testosterone treatment and time span until maximum effects are achieved. Eur J Endocrinol. 2011;165:675–85.PubMedPubMedCentralCrossRef Saad F, Aversa A, Isidori AM, Zafalon L, Zitzmann M, Gooren L. Onset of effects of testosterone treatment and time span until maximum effects are achieved. Eur J Endocrinol. 2011;165:675–85.PubMedPubMedCentralCrossRef
49.
go back to reference Wang C, Swerdloff RS, Iranmanesh A, Dobs A, Snyder PJ, Cunningham G, Matsumoto AM, Weber T, Berman the Testosterone Gel Study Group N. Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men 1. J Clin Endocrinol Metab. 2000;85:2839–53. Wang C, Swerdloff RS, Iranmanesh A, Dobs A, Snyder PJ, Cunningham G, Matsumoto AM, Weber T, Berman the Testosterone Gel Study Group N. Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men 1. J Clin Endocrinol Metab. 2000;85:2839–53.
50.
go back to reference Carrageta DF, Oliveira PF, Alves MG, Monteiro MP. Obesity and male hypogonadism: tales of a vicious cycle. Obes Rev. 2019;20:1148–58.PubMedCrossRef Carrageta DF, Oliveira PF, Alves MG, Monteiro MP. Obesity and male hypogonadism: tales of a vicious cycle. Obes Rev. 2019;20:1148–58.PubMedCrossRef
51.
go back to reference Hackett G, Cole N, Bhartia M, Kennedy D, Raju J, Wilkinson P, the BLAST Study Group. Testosterone replacement therapy improves metabolic parameters in hypogonadal men with type 2 diabetes but not in men with coexisting depression: the BLAST study. J Sex Med. 2014;11:840–56.CrossRef Hackett G, Cole N, Bhartia M, Kennedy D, Raju J, Wilkinson P, the BLAST Study Group. Testosterone replacement therapy improves metabolic parameters in hypogonadal men with type 2 diabetes but not in men with coexisting depression: the BLAST study. J Sex Med. 2014;11:840–56.CrossRef
52.
go back to reference Sharma R, Oni OA, Gupta K, et al. Normalization of testosterone level is associated with reduced incidence of myocardial infarction and mortality in men. Eur Heart J. 2015;36:2706–15.PubMedCrossRef Sharma R, Oni OA, Gupta K, et al. Normalization of testosterone level is associated with reduced incidence of myocardial infarction and mortality in men. Eur Heart J. 2015;36:2706–15.PubMedCrossRef
54.
go back to reference Golden KL, Marsh JD, Jiang Y, Moulden J. Acute actions of testosterone on contractile function of isolated rat ventricular myocytes. Eur J Endocrinol. 2005;152:479–83.PubMedCrossRef Golden KL, Marsh JD, Jiang Y, Moulden J. Acute actions of testosterone on contractile function of isolated rat ventricular myocytes. Eur J Endocrinol. 2005;152:479–83.PubMedCrossRef
55.
go back to reference Eleawa SM, Sakr HF, Hussein AM, Assiri AS, Bayoumy NMK, Alkhateeb M. Effect of testosterone replacement therapy on cardiac performance and oxidative stress in orchidectomized rats. Acta Physiol (Oxf). 2013;209:136–47.PubMedCrossRef Eleawa SM, Sakr HF, Hussein AM, Assiri AS, Bayoumy NMK, Alkhateeb M. Effect of testosterone replacement therapy on cardiac performance and oxidative stress in orchidectomized rats. Acta Physiol (Oxf). 2013;209:136–47.PubMedCrossRef
56.
57.
go back to reference Gutierrez G, Wamboldt R, Baranchuk A. The impact of testosterone on the QT interval: a systematic review. Curr Probl Cardiol. 2022;47: 100882.PubMedCrossRef Gutierrez G, Wamboldt R, Baranchuk A. The impact of testosterone on the QT interval: a systematic review. Curr Probl Cardiol. 2022;47: 100882.PubMedCrossRef
58.
go back to reference English KM, Steeds RP, Jones TH, Diver MJ, Channer KS. Low-dose transdermal testosterone therapy improves angina threshold in men with chronic stable angina: a randomized, double-blind, placebo-controlled study. Circulation. 2000;102:1906–11.PubMedCrossRef English KM, Steeds RP, Jones TH, Diver MJ, Channer KS. Low-dose transdermal testosterone therapy improves angina threshold in men with chronic stable angina: a randomized, double-blind, placebo-controlled study. Circulation. 2000;102:1906–11.PubMedCrossRef
59.
go back to reference Webb CM, Adamson DL, de Zeigler D, Collins P. Effect of acute testosterone on myocardial ischemia in men with coronary artery disease. Am J Cardiol. 1999;83(437–439):A9.PubMed Webb CM, Adamson DL, de Zeigler D, Collins P. Effect of acute testosterone on myocardial ischemia in men with coronary artery disease. Am J Cardiol. 1999;83(437–439):A9.PubMed
60.
go back to reference Rosano GM, Leonardo F, Pagnotta P, Pelliccia F, Panina G, Cerquetani E, della Monica PL, Bonfigli B, Volpe M, Chierchia SL (1999) Acute anti-ischemic effect of testosterone in men with coronary artery disease. Circulation 99:1666–1670. Rosano GM, Leonardo F, Pagnotta P, Pelliccia F, Panina G, Cerquetani E, della Monica PL, Bonfigli B, Volpe M, Chierchia SL (1999) Acute anti-ischemic effect of testosterone in men with coronary artery disease. Circulation 99:1666–1670.
61.
go back to reference Malkin CJ, Pugh PJ, Morris PD, Kerry KE, Jones RD, Jones TH, Channer KS. Testosterone replacement in hypogonadal men with angina improves ischaemic threshold and quality of life. Heart. 2004;90:871–6.PubMedPubMedCentralCrossRef Malkin CJ, Pugh PJ, Morris PD, Kerry KE, Jones RD, Jones TH, Channer KS. Testosterone replacement in hypogonadal men with angina improves ischaemic threshold and quality of life. Heart. 2004;90:871–6.PubMedPubMedCentralCrossRef
62.
go back to reference Kumanov P, Tomova A, Kirilov G. Testosterone replacement therapy in male hypogonadism is not associated with increase of endothelin-1 levels. Int J Androl. 2007;30:41–7.PubMedCrossRef Kumanov P, Tomova A, Kirilov G. Testosterone replacement therapy in male hypogonadism is not associated with increase of endothelin-1 levels. Int J Androl. 2007;30:41–7.PubMedCrossRef
63.
go back to reference Nettleship JE, Pugh PJ, Channer KS, Jones T, Jones RD. Inverse relationship between serum levels of interleukin-1beta and testosterone in men with stable coronary artery disease. Horm Metab Res. 2007;39:366–71.PubMedCrossRef Nettleship JE, Pugh PJ, Channer KS, Jones T, Jones RD. Inverse relationship between serum levels of interleukin-1beta and testosterone in men with stable coronary artery disease. Horm Metab Res. 2007;39:366–71.PubMedCrossRef
65.
go back to reference Mohamad N-V, Wong SK, Wan Hasan WN, Jolly JJ, Nur-Farhana MF, Ima-Nirwana S, Chin K-Y. The relationship between circulating testosterone and inflammatory cytokines in men. Aging Male. 2019;22:129–40.PubMedCrossRef Mohamad N-V, Wong SK, Wan Hasan WN, Jolly JJ, Nur-Farhana MF, Ima-Nirwana S, Chin K-Y. The relationship between circulating testosterone and inflammatory cytokines in men. Aging Male. 2019;22:129–40.PubMedCrossRef
66.
67.
go back to reference Di Lodovico E, Facondo P, Delbarba A, Pezzaioli LC, Maffezzoni F, Cappelli C, Ferlin A. Testosterone, hypogonadism, and heart failure. Circulation: Heart Failure 2022;15:e008755. Di Lodovico E, Facondo P, Delbarba A, Pezzaioli LC, Maffezzoni F, Cappelli C, Ferlin A. Testosterone, hypogonadism, and heart failure. Circulation: Heart Failure 2022;15:e008755.
68.
go back to reference Toma M, McAlister FA, Coglianese EE, Vidi V, Vasaiwala S, Bakal JA, Armstrong PW, Ezekowitz JA. Testosterone supplementation in heart failure. Circulation: Heart Failure 2012;5:315–321. Toma M, McAlister FA, Coglianese EE, Vidi V, Vasaiwala S, Bakal JA, Armstrong PW, Ezekowitz JA. Testosterone supplementation in heart failure. Circulation: Heart Failure 2012;5:315–321.
70.
go back to reference Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA Cancer J Clin. 1972;22:232–40.PubMedCrossRef Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA Cancer J Clin. 1972;22:232–40.PubMedCrossRef
71.
go back to reference Fowler JE, Whitmore WF. Considerations for the use of testosterone with systemic chemotherapy in prostatic cancer. Cancer. 1982;49:1373–7.PubMedCrossRef Fowler JE, Whitmore WF. Considerations for the use of testosterone with systemic chemotherapy in prostatic cancer. Cancer. 1982;49:1373–7.PubMedCrossRef
72.
go back to reference Kaplan AL, Hu JC, Morgentaler A, Mulhall JP, Schulman CC, Montorsi F. Testosterone therapy in men with prostate cancer. Eur Urol. 2016;69:894–903.PubMedCrossRef Kaplan AL, Hu JC, Morgentaler A, Mulhall JP, Schulman CC, Montorsi F. Testosterone therapy in men with prostate cancer. Eur Urol. 2016;69:894–903.PubMedCrossRef
73.
go back to reference Morgentaler A. Testosterone therapy for men at risk for or with history of prostate cancer. Curr Treat Options Oncol. 2006;7:363–9.PubMedCrossRef Morgentaler A. Testosterone therapy for men at risk for or with history of prostate cancer. Curr Treat Options Oncol. 2006;7:363–9.PubMedCrossRef
74.
go back to reference Jones SD Jr, Dukovac T, Sangkum P, Yafi FA, Hellstrom WJG. Erythrocytosis and polycythemia secondary to testosterone replacement therapy in the aging male. Sex Med Rev. 2015;3:101–12.PubMedCrossRef Jones SD Jr, Dukovac T, Sangkum P, Yafi FA, Hellstrom WJG. Erythrocytosis and polycythemia secondary to testosterone replacement therapy in the aging male. Sex Med Rev. 2015;3:101–12.PubMedCrossRef
75.
go back to reference Van Buren NL, Hove AJ, French TA, Gorlin JB. Therapeutic phlebotomy for testosterone-induced polycythemia: a blood center’s perspective. Am J Clin Pathol. 2020;154:33–7.PubMedCrossRef Van Buren NL, Hove AJ, French TA, Gorlin JB. Therapeutic phlebotomy for testosterone-induced polycythemia: a blood center’s perspective. Am J Clin Pathol. 2020;154:33–7.PubMedCrossRef
77.
go back to reference •• AbbVie. Testosterone replacement therapy for assessment of long-term vascular events and efficacy response in hypogonadal men (TRAVERSE) study. 2023. clinicaltrials.gov.This is the largest and longest randomized control trial regarding testosterone replacement therapy and cardiovascular adverse events. The data reveals that TRT is noninferior to placebo regarding CV events. •• AbbVie. Testosterone replacement therapy for assessment of long-term vascular events and efficacy response in hypogonadal men (TRAVERSE) study. 2023. clinicaltrials.​gov.​This is the largest and longest randomized control trial regarding testosterone replacement therapy and cardiovascular adverse events. The data reveals that TRT is noninferior to placebo regarding CV events.
78.
go back to reference Bhasin S, Lincoff AM, Basaria S, et al. Effects of long-term testosterone treatment on cardiovascular outcomes in men with hypogonadism: rationale and design of the TRAVERSE study. Am Heart J. 2022;245:41–50.PubMedCrossRef Bhasin S, Lincoff AM, Basaria S, et al. Effects of long-term testosterone treatment on cardiovascular outcomes in men with hypogonadism: rationale and design of the TRAVERSE study. Am Heart J. 2022;245:41–50.PubMedCrossRef
Metadata
Title
Testosterone Replacement Therapy and Cardiovascular Disease: Balancing Safety and Risks in Hypogonadal Men
Authors
Kelli Blackwell
Michele Blackwell
Thomas Blackwell
Publication date
21-09-2023
Publisher
Springer US
Published in
Current Cardiology Reports / Issue 10/2023
Print ISSN: 1523-3782
Electronic ISSN: 1534-3170
DOI
https://doi.org/10.1007/s11886-023-01935-1

Other articles of this Issue 10/2023

Current Cardiology Reports 10/2023 Go to the issue

Global Cardiovascular Health (L Sperling and D Gaita, Section Editors)

Improving Hypertension Control in Vulnerable Populations Around the World

Women and Cardiovascular Health (N Goldberg and S Lewis, Section Editors)

Challenges in Cardiovascular Imaging in Women with Breast Cancer

Cardiovascular Critical Care (A Higgins and R Lee, Section Editors)

Training pathways in critical care cardiology

Global Cardiovascular Health (L Sperling and D Gaita, Section Editors)

Role of arterial stiffness in cardiovascular health